Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
37.2 USD -0.77% Intraday chart for Spyre Therapeutics, Inc. +0.19% +72.86%
Mar. 26 Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating MT
Mar. 18 Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating
MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding
CI
North American Morning Briefing : Powell Still in -2-
DJ
Spyre Therapeutics Announces Grants of Inducement Awards
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12
MT
Spyre Therapeutics: Q4 Earnings Snapshot
AQ
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PR
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
PR
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation
AQ
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
AQ
Spyre Therapeutics, Inc. Announces Board Changes
CI
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors
CI
Spyre Therapeutics Announces Grants of Inducement Awards
PR
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.